Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals

BACKGROUND: Idarucizumab, a monoclonal antibody fragment that reverses the anticoagulant effect of dabigatran, was approved for use in Canada in 2016. OBJECTIVE: Our objective was to assess the safety of idarucizumab among patients who received the drug within the first 3 years of its use in Canada....

Descripción completa

Detalles Bibliográficos
Autores principales: Abdulrehman, Jameel, Zarabi, Sahar, Elbaz, Carolyne, de Wit, Kerstin, Lin, Yulia, Sholzberg, Michelle, Selby, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348998/
https://www.ncbi.nlm.nih.gov/pubmed/34401639
http://dx.doi.org/10.1002/rth2.12535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348998/
https://www.ncbi.nlm.nih.gov/pubmed/34401639
http://dx.doi.org/10.1002/rth2.12535

Ejemplares similares